Unavailable
Unavailable
Save time and jump to the most important pieces.
CHICAGO, IL / ACCESSWIRE / March 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the initiation of the development of Cloudscreen 2.0, the new iteration of its groundbreaking Artificial Intelligence (AI) drug repurposing platform.As previously announced, on January 23, 2024, Cosmos Health completed the acquisition of Cloudscreen. Building on the success of its predecessor, Cloudscreen 2.0 represents a sign
CHICAGO, IL / ACCESSWIRE / January 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of Cloudscreen®, a cutting-edge Artificial Intelligence (AI) powered platform. The acquisition is pursuant to the purchase agreement announced on October 11, 2023.Cloudscreen is a multimodal platform specialized in drug repurposing, a process that involves uncovering new tar
CHICAGO, IL / ACCESSWIRE / January 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has successfully completed the acquisition of the licenses and rights of a comprehensive portfolio of 10 generic drugs from a related party for €3.2 million, or approximately $3.5 million at today's exchange rate.This strategic acquisition significantly enhances Cosmos Health's pharmaceutical portfolio. The selected d
4 - Cosmos Health Inc. (0001474167) (Issuer)
4 - Cosmos Health Inc. (0001474167) (Issuer)
4 - Cosmos Health Inc. (0001474167) (Issuer)
CHICAGO, IL / ACCESSWIRE / November 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its healthcare distribution business, operated through its wholly owned subsidiary, CosmoFarm S.A. ("CosmoFarm"), has achieved record sales.In the first ten months of 2024, CosmoFarm achieved record revenue of approximately $43 million, representing an 8.62% increase over the same period last year and contributing to a
CHICAGO, IL / ACCESSWIRE / September 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that sales of its proprietary brands, including Sky Premium Life, on Amazon in the United Kingdom have surged by 160%, increasing to $596,000 year-to-date in 2024 from $230,000 during the same period in 2023.Greg Siokas, CEO of Cosmos Health, stated: "We are delighted that our proprietary brands are being very well receive
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received its first round of purchase orders in the United Kingdom (UK) for its antimicrobial wash, C-Scrub Wash Chlorhexidine 4% ('C-Scrub'), exceeding $500,000. The orders cover the period from July 2024 to September 2024.Cosmos Health is in the process of securing additional orders for October 2024 and beyond
SC 13G - Cosmos Health Inc. (0001474167) (Subject)
SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)
SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)
DEFA14A - Cosmos Health Inc. (0001474167) (Filer)
S-1 - Cosmos Health Inc. (0001474167) (Filer)
DEF 14A - Cosmos Health Inc. (0001474167) (Filer)
4 - Cosmos Health Inc. (0001474167) (Issuer)
4 - Cosmos Health Inc. (0001474167) (Issuer)
THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded
CHICAGO, IL / ACCESSWIRE / August 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today the engagement of KPMG Certified Auditors S.A. ("KPMG") as the Company's independent registered public accounting firm, effective August 7, 2023. KPMG replaces the Company's former auditor, Armanino LLP.The appointment of KPMG was made by the Cosmos Health Board of Directors at the recommendation of its Audit Committee. The decision to change auditors was not the result of any disagreement between the Company
CHICAGO, IL / ACCESSWIRE / February 1, 2023 / Cosmos Health Inc. ("the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, is pleased to announce the appointment of Nikos Bardakis, who comes with over two decades of international branded pharmaceutical sector experience, as the Chief Operating Officer (COO).As the Chief Operating Officer at Cosmos Health, Mr. Bardakis' objective will be to bring new capabilities and processes into the organization for optimizing operational excellence towards global commercial expansion of Cosmos' premium products. In addition, M